HYBRID EVENT: You can participate in person at Singapore or Virtually from your home or work.
2nd Edition of International Cancer & Immuno-Oncology Conference
March 19-21, 2026 | Singapore
Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments.
Immunotherapy: Checkpoint inhibitors, CAR-T cell therapy, and vaccine-based treatments.
Immunotherapy represents a paradigm shift in cancer treatment, harnessing the body’s immune system to combat tumors. Case studies featuring therapies like checkpoint inhibitors, CAR-T cells, and cancer vaccines demonstrate their transformative potential. For example, pembrolizumab’s success in treating metastatic melanoma has opened doors for its use in other cancers. These cases also highlight challenges, such as managing immune-related adverse events and identifying biomarkers to predict response. By documenting successes and obstacles, these studies provide a roadmap for refining immunotherapy and expanding its application to more cancer types, ultimately improving patient outcomes.
Committee Members
Rajvir Dahiya
University of California San Francisco, United States
Atif A Ahmed
University of Washington-Seattle Children’s Hospital, United States
Anyou Wang
DIFIBER LLC, United States CIOC 2026 Speakers
Paulo Cesar De Morais
Catholic University of Brasilia, Brazil
Allen Chen
Olympic Medical Center, United States
Shilpa S Dhar
UT MD Anderson Cancer Center, United States
Ritu Khanna
University of Manchester, United KingdomSubmit your abstract Today
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China